Denosumab for treatment of hypercalcemia of malignancy

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3144-3152

  Hu, Mimi I ^a   Glezerman, Ilya G ^b   Leboulleux, Sophie ^c   Insogna, Karl ^d   Gucalp, Rasim ^e   Misiorowski, Waldemar ^f   Yu, Bennett ^g   Zorsky, Paul ^h   Tosi, Diego ⁱ   Bessudo, Alberto ^j   Jaccard, Arnaud ^k   Tonini, Giuseppe ^l   Ying, Wendy ^m   Braun, Ada ^m   Jain, Rajul K ^m  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h Peninsula Regional Medical Center   (United States)

ⁱ CENTRE VAL D AURELLE   (France)

^j Department of Medical Oncology Hematology California Cancer Associates for Research and Excellence   (United States)

^k LIMOGES UNIVERSITY HOSPITAL   (France)

^l Policlinico Universitario Campus Bio Medico   (Italy)

^m AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; SERUM ALBUMIN; TNFSF11 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; HYPOXIA; LIVER FAILURE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; REACTION TIME; SURVIVAL TIME; TACHYCARDIA; TREATMENT DURATION; TREATMENT FAILURE; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG THERAPY; ETIOLOGY; GASTROINTESTINAL DISEASE; HYPOPHOSPHATEMIA; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; OSTEOLYSIS; THERAPY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPERCALCEMIA; HYPOPHOSPHATEMIA; INTERNATIONALITY; MALE; MIDDLE AGED; NEOPLASMS; RANK LIGAND; SERUM ALBUMIN; THERAPEUTICS; YOUNG ADULT;

EID: 84907200658     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1001     Document Type: Article

References (24)

1. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-Associated hypercalcemia. Clin J Am Soc Nephrol. 2012; 7: 1722-1729.
2. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352: 373-379.
3. Gastanaga V, Jain R, Pirolli M, et al. Prevalence of hypercalcemia of malignancy in the United States: projection methods using oncology electronic health records (EHR). Eur J Cancer. 2013; 49: S1-S1028, Abstract 1415, p. 25.
4. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990; 112: 499-504.
5. Burtis WJ, Wu T, Bunch C, et al. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem. 1987; 262: 7151-7156.
6. Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormone-related protein purified from ahumanlung cancer cell line. Proc Natl Acad Sci U S A. 1987; 84: 5048-5052.
7. Strewler GJ, Stern PH, Jacobs JW, et al. Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest. 1987; 80: 1803-1807.
8. Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med. 1994; 45: 189-200.
9. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008; 149: 259-263.
10. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19: 558-567.
11. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001; 28: 17-24.
12. Aredia (pamidronate disodium) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
13. Zometa (zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
14. Morony S, Warmington K, Adamu S, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology. 2005; 146: 3235-3243.
15. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001; 61: 2572-2578.
16. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-822.
17. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 1125-1132.
18. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-5139.
19. Diel IJ, Body JJ, Stopeck AT, et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2011; 47: S237, Abstract 3051.
20. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013; 105: 1417-1420.
21. Cancer Therapy Evaluation Program.CommonTerminology Criteria for Adverse Events (CTCAE), Version 3.0. http://ctep.cancer.gov/protocoldevelopment/electronic-Applications/docs/ctcaev3.pdf. Accessed August 8, 2013.
22. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010; 11: 275-280.
23. XGEVA (denosumab solution for injection). Product monograph. Amgen Canada Inc; 2013.
24. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14: 901-908.